| Cases n (%) | Controls n (%) | p |
---|---|---|---|
First line therapy | 81 (100) | 162 (100) | Â |
Combinations | Â | Â | Â |
-NRTI+PI | 67 (83) | 138 (85) | 0.7 |
-NRTI+NNRTI | 14 (17) | 26 (16) | 0.7 |
Duration; months (mean ± SD) | 13.46 ± 10.23 | 16.67 ± 8.45 | 0.06 |
N° of patients who suspended | 53 (66) | 91 (56) | 0.2 |
Cause of suspension | Â | Â | Â |
-side effects | 30 (56) | 37 (41) | 0.1 |
-viro-immunological failure | 8 (15) | 15 (17) | 0.6 |
Second line therapy | 45 (56) | 91 (56) | 1 |
Third line therapy | 11 (14) | 31 (19) | 0.4 |
Total number of drug changes (mean ± SD) | 2.1 ± 0.9 | 2.0 ± 0.6 | 0.8, |
Adherent to the last drug regimen | 68 (84) | 118 (73) | 0.08 |
Side effects to HAART | Â | Â | Â |
dyslipidemia | 32 (40) | 55 (34) | 0.5 |
digestive intolerance | 26 (32) | 58 (36) | 0.6 |
lipodystrophy | 12 (15) | 23 (14) | 0.7 |
hyperglycaemia | 8 (10) | 3 (2) | 0.01 |
anaemia | 8 (10) | 3 (2) | 0.01 |